文献速递肝病

真实世界实践中全口服直接抗病毒药物治疗人类免疫缺陷病毒/丙型肝炎病毒合并感染者的疗效:马德里合并感染登记研究

All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
PubMed 文献 · Hepatology · 2018-04-27

该研究基于马德里地区2014年11月至2016年8月的前瞻性登记,评估2369例HIV/HCV合并感染者接受无干扰素直接抗病毒药物治疗后的持续病毒学应答。总体意向性分析持续病毒学应答率为92.0%(95%CI 90.9%-93.1%),无肝硬化、代偿性肝硬化和失代偿性肝硬化患者分别为93.8%、91.0%和80.8%。治疗失败预测因素包括男性、CDC C类、基线CD4+ T细胞计数<200/mm3、HCV RNA载量≥800,000 IU/mL、失代偿性肝硬化及使用次优方案。

要点

  • 总体持续病毒学应答率为92.0%(95%CI 90.9%-93.1%),失代偿性肝硬化患者为80.8%(95%CI 73.7%-86.6%)。
  • 治疗失败预测因素包括男性、CDC C类、基线CD4+ T细胞计数<200/mm3、HCV RNA≥800,000 IU/mL和失代偿性肝硬化。
  • 因不良事件停药的患者不足1%。

核心结论

  • 在这项大型真实世界研究中,基于直接抗病毒药物的治疗对合并感染者安全且高效;失败预测因素包括性别、HIV相关免疫抑制、HCV RNA载量、肝病严重程度及使用次优直接抗病毒药物方案。

研究设计与样本

  • 前瞻性登记研究,纳入马德里地区医院2014年11月至2016年8月期间接受无干扰素直接抗病毒药物治疗的HIV/HCV合并感染者,共评估2369例患者。

主要发现

  • 总体意向性分析持续病毒学应答率为92.0%(95%CI 90.9%-93.1%)。
  • 无肝硬化患者持续病毒学应答率为93.8%(95%CI 92.4%-95.0%),代偿性肝硬化患者为91.0%(95%CI 88.8%-92.9%),失代偿性肝硬化患者为80.8%(95%CI 73.7%-86.6%)。
  • 治疗失败相关因素:男性调整OR 1.75(95%CI 1.14-2.69),CDC C类调整OR 1.65(95%CI 1.12-2.41),基线CD4+ T细胞计数<200/mm3调整OR 2.30(95%CI 1.35-3.92),HCV RNA载量≥800,000 IU/mL调整OR 1.63(95%CI 1.14-2.36),代偿性肝硬化调整OR 1.35(95%CI 0.96-1.89),失代偿性肝硬化调整OR 2.92(95%CI 1.76-4.87)。
  • 使用索磷布韦联合西美瑞韦、索磷布韦联合利巴韦林、西美瑞韦联合达拉他韦与治疗失败相关。
  • 因不良事件停药的患者不足1%。

关键数值与推荐

  • 治疗方案包括索磷布韦/雷迪帕韦(61.9%)、索磷布韦联合达拉他韦(14.6%)、达沙布韦联合奥比他韦/帕利瑞韦/利托那韦(13.2%)及其他方案(10.3%)。
  • 利巴韦林用于30.6%的患者。
  • 主要HCV基因型为1a(40.9%)、4(22.4%)、1b(15.1%)和3(15.0%)。
  • 患者中无肝硬化者占59.5%,代偿性肝硬化者占33.9%,失代偿性肝硬化者占6.6%。

临床怎么用

  • 基于直接抗病毒药物的治疗在HIV/HCV合并感染者中安全且高效。
  • 应关注男性、CDC C类、基线CD4+ T细胞计数<200/mm3、HCV RNA载量≥800,000 IU/mL、失代偿性肝硬化及使用次优方案等治疗失败预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients treated with interferon-free direct-acting antiviral agent-based therapy in hospitals from the region of Madrid between November 2014 and August 2016. We assessed sustained viral response at 12 weeks after completion of treatment and used multivariable logistic regression to identify predictors of treatment failure. We evaluated 2,369 patients, of whom 59.5% did not have cirrhosis, 33.9% had compensated cirrhosis, and 6.6% had decompensated cirrhosis. The predominant HCV genotypes were 1a (40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens included sofosbuvir (SOF)/ledipasvir (61.9%), SOF plus daclatasvir (14.6%), dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), and other regimens (10.3%). Ribavirin was used in 30.6% of patients. Less than 1% of patients discontinued therapy owing to adverse events. The frequency of sustained viral response by intention-to-treat analysis was 92.0% (95% confidence interval, 90.9%-93.1%) overall, 93.8% (92.4%-95.0%) for no cirrhosis, 91.0% (88.8%-92.9%) for compensated cirrhosis, and 80.8% (73.7%-86.6%) for decompensated cirrhosis. The factors associated with treatment failure were male sex (adjusted odds ratio, 1.75; 95% confidence interval, 1.14-2.69), Centers for Diseases Control and Prevention category C (adjusted odds ratio, 1.65; 95% confidence interval, 1.12-2.41), a baseline cluster of differentiation 4-positive (CD4+) T-cell count <200/mm3 (adjusted odds ratio, 2.30; 95% confidence interval, 1.35-3.92), an HCV RNA load ≥800,000 IU/mL (adjusted odds ratio, 1.63; 95% confidence interval, 1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35; 95% confidence interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95% confidence interval, 1.76-4.87), and the use of SOF plus simeprevir, SOF plus ribavirin, and simeprevir plus daclatasvir. CONCLUSION: In this large real-world study, direct-acting antiviral agent-based therapy was safe and highly effective in coinfected patients; predictors of failure included gender, human immunodeficiency virus-related immunosuppression, HCV RNA load, severity of liver disease, and the use of suboptimal direct-acting antiviral agent-based regimens. (Hepatology 2018;68:32-47).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Berenguer J, Gil-Martin Á, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018. PMID: 29377274. doi:10.1002/hep.29814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。